Reuters -- Stock in Swiss drug company Novartis is poised to rise as the company’s pipeline of new drugs is one of the most promising in the industry, Barron’s business weekly said on Sunday.
Reuters -- Stock in Swiss drug company Novartis is poised to rise as the company’s pipeline of new drugs is one of the most promising in the industry, Barron’s business weekly said on Sunday.
